Gustavo Viani: Cost-effective and Accessible treatment in LMICs for advanced gall bladder cancer
Gustavo Viani, Professor of Radiation Oncology at Ribeirão Preto Medical School, University of Sao Paulo, recently posted on X:
“CTRT significantly high survival and offers a cost-effective, accessible treatment in LMICs for advanced gall bladder cancer
Objective:
Investigate consolidation CTRT vs. observation after
First-line chemotherapy (gemcitabine + cisplatin) in unresectable advanced GBC with stable disease or partial response
Methods:
135 participants, randomized (CTRT: 45 Gy/25 fractions + 9 Gy boost + capecitabine) or obs
Results:
•Median OS: CTRT 10 m vs. observation 4 m (HR 0.43; p<0.001)
•PFS: CTRT 7 m vs. observation 1 m
•1-y OS: CTRT 39.7% vs. observation 7.5%
•Minimal grade 3+ toxicities; no QoL.”
Authors: Sushma Agrawal, Vishwas Kapoor, Rahul Rahul, Ashish Singh, Prabhakar Mishra, Rajan Saxena,
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023